RhumbLine Advisers’s Avadel Pharmaceuticals AVDL Stock Holding History

RhumbLine Advisers’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-107,493	Closed	-$2.32M	–	4100
2025 Q4	$2.32M	Sell	107,493 -20,074	-16%	-$390K	﹤0.01%	1795
2025 Q3	$1.95M	Sell	127,567 -4,411	-3%	-$57.4K	﹤0.01%	1926
2025 Q2	$1.17M	Buy	131,978 +4,951	+4%	+$43.5K	﹤0.01%	2167
2025 Q1	$995K	Buy	127,027 +2,890	+2%	+$24.2K	﹤0.01%	2173
2024 Q4	$1.3M	Buy	124,137 +2,492	+2%	+$30.3K	﹤0.01%	2106
2024 Q3	$1.6M	Sell	121,645 -1,030	-0.8%	-$15.7K	﹤0.01%	2026
2024 Q2	$1.72M	Buy	122,675 +121,130	+7,840%	+$1.97M	﹤0.01%	1963
2024 Q1	$26.1K	Buy	1,545 +289	+23%	+$4.3K	﹤0.01%	3731
2023 Q4	$17.7K	Hold	1,256	–	–	﹤0.01%	3787
2023 Q3	$12.9K	Sell	1,256 -65	-5%	-$871	﹤0.01%	3835
2023 Q2	$21.8K	Buy	+1,321	New	+$17.2K	﹤0.01%	3800

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

RhumbLine Advisers's AVDL Position: Q1 2026 in Review

RhumbLine Advisers sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 107,493 shares — an estimated $2.32M sold.

RhumbLine Advisers first reported a position in AVDL in Q2 2023 and held it in 11 quarters. The position peaked at $2.32M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

RhumbLine Advisers reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
RhumbLine Advisers sold 107,493 Avadel Pharmaceuticals shares in Q1 2026, an estimated $2.32M.
RhumbLine Advisers first reported a position in Avadel Pharmaceuticals in Q2 2023 and held it in 11 quarters.
RhumbLine Advisers's Avadel Pharmaceuticals position peaked at $2.32M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.